Johnson & Johnson (Nyse:Jnj) is one of the actions that Jim Cramer has put under a microscope. Cramer recalled his discussion with the CEO of the company and commented:
“What could work on the show on the show last Friday, we had Joaquin Duato. He is Johnson & Johnson CEO, and he told a remarkable story about cancer drugs and revolutionary medical devices, especially their excellent cardio products. Now, I was worried about the court prosecution of the Talc they have, but I believe that the risk of the Amifest and the baby powder that was being done in the process of being done in the process of being made in the scenarios. Finally, I bet that the complainants will realize that it is simply too expensive to continue to take J & J. »»
Gil C / Shutterstock.com
Johnson & Johnson (NYSE: JNJ) develops pharmaceuticals and medical technologies covering immunology, oncology, neuroscience, infectious diseases, cardiovascular care and pulmonary hypertension. In addition, the company provides surgical solutions, orthopedies, vision care and neurovascular products.
Although we recognize JNJ’s potential as an investment, we believe that certain AI actions offer greater upward potential and have a less unknown risk. If you are looking for an extremely undervalued AI stock that should also benefit considerably from the Trump era tariffs and the excessive trend, see our free report on the Best short -term AI stock.
Read then: 30 actions that should double in 3 years And 11 Hidden AI stocks to buy now.
Disclosure: None. This article is initially published at Initiate monkey.
